Laurus Labs Reports 148% Profit Surge in FY26 on Strong Revenue Growth

Laurus Labs' revenue grew 23% year-on-year to ₹6,813 crore, while net profit surged 148% to ₹889 crore in FY26. Strong performance in CDMO and Generics drove results, with expansion plans underway.

What Happened

Laurus Labs announced strong financial results for the full fiscal year 2026 (FY26).

Revenue increased by 23% year-on-year to ₹6,813 crore. Net profit surged by 148%, reaching ₹889 crore.

EBITDA saw a substantial 64% rise to ₹1,826 crore, reflecting improved operational efficiency and margins. Earnings per share (EPS) also jumped 148% to ₹16.4.

The company declared an interim dividend of ₹1.20 per share.

Why It Matters

This impressive growth was driven by strong performance in its Contract Development and Manufacturing Organization (CDMO) and Affordable Medicines (Generics) divisions.

The CDMO segment revenue grew 36% year-on-year, showing its increasing importance. The Generics division also achieved healthy growth with an 18% revenue increase.

These results highlight Laurus Labs' effective execution of its strategy and successful use of its diversified business model.

Company Strategy and Investments

Laurus Labs has been strategically investing in expanding its capacity and developing new technology platforms.

The company is undertaking significant capital expenditure (CAPEX), with ₹1,070 crore invested in FY26. It also plans a substantial ~$600 million (approx. ₹5,000 crore) investment over eight years for a new 532-acre advanced manufacturing complex in Visakhapatnam (Vizag).

Its CDMO business has seen rapid expansion, with revenues more than doubling year-on-year in Q1 FY26, positioning it as a key player. Recent strategic moves include a stake in Aarvik Therapeutics to develop Antibody-drug conjugate (ADC) technology.

For FY25, the company had reported a net profit growth of 126.1% to ₹380.4 crore on revenue of ₹5,317.5 crore, alongside improving EBITDA margins.

Key Financial Improvements and Outlook

• Higher Profits and EPS: Shareholders benefit from a substantial increase in net profit and EPS, reflecting better operational performance.
• Improved Debt Levels: A Net Debt-to-EBITDA ratio of 1.3x (down from 2.3x in FY25) indicates a stronger balance sheet.
• Investment in Future Growth: Significant investments in CAPEX and new technology platforms like Gene Therapy/ADC signal a focus on long-term expansion.
• Shareholder Returns: The interim dividend offers a direct return to shareholders.
• De-risked Business Model: Continued strong performance from CDMO and Generics divisions reduces reliance on any single segment.

Key Risks and Challenges

• Regulatory Scrutiny: Pharmaceutical companies face regulatory hurdles. An FDA "untitled letter" in May 2024 cited quality control issues at a subsidiary, requiring ongoing compliance vigilance.
• Valuation and CAPEX Pressure: While results are strong, some analysts caution about high valuations and significant future CAPEX plans, which could pressure short-term margins.
• CAPEX Execution: Successfully implementing the large CAPEX for the Vizag site and other projects is crucial for achieving future growth targets.
• Tax Matters: Although an IT penalty from 2025 was deemed financially insignificant, tax-related issues are a point of attention in the pharma sector.

Competitive Landscape

Laurus Labs operates in a competitive market alongside major Indian pharmaceutical companies like Divi's Laboratories, Syngene International, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries. Its growing focus on CDMO services also places it in competition with specialized service providers.

Key Metrics Summary

• Full Year FY26 Revenue: ₹6,813 Cr (Consolidated)
• Full Year FY26 Net Profit: ₹889 Cr (Consolidated)
• Full Year FY26 EBITDA: ₹1,826 Cr (Consolidated)
• Full Year FY26 ROCE: 17.7%
• Net Debt-to-EBITDA: Improved to 1.3x in FY26 from 2.3x in FY25.

What to Track Next

• Vizag Site Progress: Monitor developments and timelines for the new ₹5,000 crore Vizag manufacturing complex.
• Gene Therapy/ADC Platform: Track the company's investments and progress in these advanced biotechnology areas.
• CDMO Segment Growth: Continued strong performance and client wins in the CDMO business will be key.
• Margin Sustainability: Watch if the expanded margins achieved in FY26 can be sustained amidst ongoing investments and potential cost pressures.
• Future Guidance: Upcoming management commentary and guidance for FY27 and beyond.